生物股份（600201）(600201.SH)发布公告，基于对公司未来持续稳定发展的信心和长期投资价值的认 可，增强投资者信心，公司大股东内蒙古金宇生物控股有限公司(简称"生物控股")计划自公告披露之日 起12个月内，通过上海证券交易所系统以集中竞价方式增持公司股份，增持总金额不低于人民币5000万 元，不超过人民币1亿元。 ...

朸濬国际(01355)发布公告，于2025年12月23日，本公司直接全资附属公司佳怡环球作为买方与卖方郑 彤女士订立买卖协议，卖方有条件同意出售而买方有条件同意购买销售股份(占目标公司奥诺香港已发 行股本的100%)及销售贷款，总作价为2200万港元。于完成后，目标公司将成为本公司的间接全资附属 公司及本公司将持有倍生生物的37.5%权益，倍生生物集团的财务业绩、资产及负债将以权益法会计处 理计入在本集团的财务报表。 倍生生物是专注于菌株设计和发酵工艺开发的合成生物基础设施供应商，为合成生物企业、生物医药企 业及希望利用合成生物技术实现产业升级的传统发酵企业提供更高品质、更便捷、更低成本的技术服务 及相关产品。 本集团认为，医疗保健及美容业务相关专有权利与技术的研发是取得竞争优势的关键。本集团目前的研 发重点领域包括：III型胶原蛋白-透明质酸"双蛋白"水光针，主要采用透明质酸渗透增强技术，以重组 III型胶原蛋白+乙酰化透明质酸(AcHA)为复合成分，提高透皮吸收效率，从而实现即时填充+长期再生; 羟基磷灰石/胶原蛋白复合填料，瞄准颞部填料这一庞大市场;光电激活型胶原蛋白修护精华，主要目标 是开发含有热敏/ ...

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

每经AI快讯，生物股份（SH 600201，收盘价：16.9元）12月23日晚间发布公告称，基于对公司未来持 续稳定发展的信心和长期投资价值的认可，增强投资者信心，大股东内蒙古金宇生物控股有限公司（简 称"生物控股"）计划自本公告披露之日起12个月内，通过上海证券交易所系统以集中竞价方式增持公司 股份，增持总金额不低于人民币5000万元，不超过人民币1亿元，本次增持计划不设置固定价格、价格 区间，生物控股将基于对公司股票价值的合理判断，并根据公司股票价格波动情况及资本市场整体趋 势，择机实施本次增持计划。 2024年1至12月份，生物股份的营业收入构成为：生物制药占比94.42%，其他行业占比3.18%，其他业 务占比2.4%。 截至发稿，生物股份市值为188亿元。 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 （记者 王晓波） ...

智通财经APP讯，生物股份(600201.SH)发布公告，基于对公司未来持续稳定发展的信心和长期投资价 值的认可，增强投资者信心，公司大股东内蒙古金宇生物控股有限公司(简称"生物控股")计划自公告披 露之日起12个月内，通过上海证券交易所系统以集中竞价方式增持公司股份，增持总金额不低于人民币 5000万元，不超过人民币1亿元。 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-062 金宇生物技术股份有限公司 关于大股东增持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 增持主体名称 | 内蒙古金宇生物控股有限公司 | | | | --- | --- | --- | --- | | 增持主体身份 | 控股股东、实控人 | 是 | 否 | | | 控股股东、实控人的一致行动人 | 是 | 否 | | | 直接持股 5%以上股东 | 是 | 否 | | | 董事、监事和高级管理人员 | 是 | 否 | 上述增持主体存在一致行动人： | 股东名称 | 持股数量 （股） | 持股比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | | 内蒙古金宇生 | | | 张翀宇持有生物控股 39.00%股 | | 物控股有限公 | 122,304,000 | 11.00% | 权，张竞持有生物控股 51.93% | | 司 | | | 股权，张翀宇与张竞系 ...

Core Viewpoint - The major shareholder of the company, Inner Mongolia Jinyu Biological Holdings Co., Ltd., plans to increase its stake in the company by purchasing additional A-shares through the Shanghai Stock Exchange from December 24, 2025, to December 23, 2026, with an investment amount ranging from 50 million to 100 million yuan [1] Group 1 - The major shareholder currently holds 122 million shares, accounting for 11.00% of the company's total shares [1] - The planned increase in shareholding does not have a fixed price range, and the funds will come from self-owned and self-raised sources [1] - The major shareholder has committed not to reduce its holdings during the implementation period of the increase and for the statutory period after completion [1]

格隆汇12月23日丨生物股份(600201.SH)公布，基于对公司未来持续稳定发展的信心和长期投资价值的 认可，增强投资者信心，生物控股计划自本公告披露之日起12个月内，通过上海证券交易所系统以集中 竞价方式增持公司股份，增持总金额不低于人民币5000万元，不超过人民币10000万元（以下简称"本次 增持计划"），本次增持计划不设置固定价格、价格区间，生物控股将基于对公司股票价值的合理判 断，并根据公司股票价格波动情况及资本市场整体趋势，择机实施本次增持计划。 ...

格隆汇12月23日丨生物股份(600201.SH)公布，基于对公司未来持续稳定发展的信心和长期投资价值的 认可，增强投资者信心，生物控股计划自本公告披露之日起12个月内，通过上海证券交易所系统以集中 竞价方式增持公司股份，增持总金额不低于人民币5000万元，不超过人民币10000万元（以下简称"本次 增持计划"），本次增持计划不设置固定价格、价格区间，生物控股将基于对公司股票价值的合理判 断，并根据公司股票价格波动情况及资本市场整体趋势，择机实施本次增持计划。 ...

生物股份公告，公司大股东内蒙古金宇生物控股有限公司持股1.22亿股，占11.00%，计划自2025年12月 24日至2026年12月23日通过上海证券交易所集中竞价增持公司A股，增持金额5000万元～1亿元，不设 固定价格区间，资金来源为自有及自筹，并承诺在增持计划实施期间及实施完成后法定期限内不减持所 持股份。 ...